Literature DB >> 33552133

Gene Expression Changes and Associated Pathways Involved in the Progression of Prostate Cancer Advanced Stages.

Elena A Pudova1, George S Krasnov1, Anastasiya A Kobelyatskaya1, Maria V Savvateeva1, Maria S Fedorova1, Vladislav S Pavlov1, Kirill M Nyushko2, Andrey D Kaprin2, Boris Y Alekseev2, Dmitry Y Trofimov3, Gennady T Sukhikh3, Anastasiya V Snezhkina1, Anna V Kudryavtseva1.   

Abstract

Prostate cancer (PC) is one of the most common cancers among men worldwide, and advanced PCs, such as locally advanced PC (LAPC) and castration-resistant PC (CRPC), present the greatest challenges in clinical management. Current indicators have limited capacity to predict the disease course; therefore, better prognostic markers are greatly needed. In this study, we performed a bioinformatic analysis of The Cancer Genome Atlas (TCGA) datasets, including RNA-Seq data from the prostate adenocarcinoma (PRAD; n = 55) and West Coast Dream Team - metastatic CRPC (WCDT-MCRPC; n = 84) projects, to evaluate the transcriptome changes associated with progression-free survival (PFS) for LAPC and CRPC, respectively. We identified the genes whose expression was positively/negatively correlated with PFS. In LAPC, the genes with the most significant negative correlations were ZC2HC1A, SQLE, and KIF11, and the genes with the most significant positive correlations were SOD3, LRRC26, MIR22HG, MEG3, and MIR29B2CHG. In CRPC, the most significant positive correlations were found for BET1, CTAGE5, IFNGR1, and GIMAP6, and the most significant negative correlations were found for CLPB, PRPF19, ZNF610, MPST, and LINC02001. In addition, we performed a gene network interaction analysis using STRINGdb, which revealed a significant relationship between genes predominantly involved in the cell cycle and characterized by upregulated expression in early recurrence. Based on the results, we propose several genes that can be used as potential prognostic markers.
Copyright © 2021 Pudova, Krasnov, Kobelyatskaya, Savvateeva, Fedorova, Pavlov, Nyushko, Kaprin, Alekseev, Trofimov, Sukhikh, Snezhkina and Kudryavtseva.

Entities:  

Keywords:  PFS; PRAD; TCGA; WCDT-MCRPC; gene expression; prostate cancer

Year:  2021        PMID: 33552133      PMCID: PMC7859645          DOI: 10.3389/fgene.2020.613162

Source DB:  PubMed          Journal:  Front Genet        ISSN: 1664-8021            Impact factor:   4.599


  40 in total

1.  clusterProfiler: an R package for comparing biological themes among gene clusters.

Authors:  Guangchuang Yu; Li-Gen Wang; Yanyan Han; Qing-Yu He
Journal:  OMICS       Date:  2012-03-28

2.  EZH2-mediated inactivation of IFN-γ-JAK-STAT1 signaling is an effective therapeutic target in MYC-driven prostate cancer.

Authors:  Zhen Ning Wee; Zhimei Li; Puay Leng Lee; Shuet Theng Lee; Yoon Pin Lim; Qiang Yu
Journal:  Cell Rep       Date:  2014-06-19       Impact factor: 9.423

Review 3.  Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death.

Authors:  Beth A A Weaver; Don W Cleveland
Journal:  Cancer Cell       Date:  2005-07       Impact factor: 31.743

4.  lncRNA MEG3 inhibit proliferation and metastasis of gastric cancer via p53 signaling pathway.

Authors:  G-H Wei; X Wang
Journal:  Eur Rev Med Pharmacol Sci       Date:  2017-10       Impact factor: 3.507

Review 5.  Vascular protection: superoxide dismutase isoforms in the vessel wall.

Authors:  Frank M Faraci; Sean P Didion
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-05-27       Impact factor: 8.311

Review 6.  Drug discovery in advanced prostate cancer: translating biology into therapy.

Authors:  Timothy A Yap; Alan D Smith; Roberta Ferraldeschi; Bissan Al-Lazikani; Paul Workman; Johann S de Bono
Journal:  Nat Rev Drug Discov       Date:  2016-07-22       Impact factor: 84.694

7.  CAPC negatively regulates NF-κB activation and suppresses tumor growth and metastasis.

Authors:  X-F Liu; L Xiang; Y Zhang; K G Becker; T K Bera; I Pastan
Journal:  Oncogene       Date:  2011-08-08       Impact factor: 9.867

8.  LncRNA MEG3 inhibits the progression of prostate cancer by modulating miR-9-5p/QKI-5 axis.

Authors:  Meng Wu; Yawei Huang; Tongchang Chen; Weichao Wang; Shiguang Yang; Zhenfeng Ye; Xiaoqing Xi
Journal:  J Cell Mol Med       Date:  2018-11-22       Impact factor: 5.310

9.  Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance.

Authors:  Sanjib Bhattacharyya; Sounik Saha; Karuna Giri; Ian R Lanza; K Sreekumar Nair; Nicholas B Jennings; Cristian Rodriguez-Aguayo; Gabriel Lopez-Berestein; Eati Basal; Amy L Weaver; Daniel W Visscher; William Cliby; Anil K Sood; Resham Bhattacharya; Priyabrata Mukherjee
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

10.  Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2- metastatic breast cancer.

Authors:  Anna Forsythe; David Chandiwana; Janina Barth; Marroon Thabane; Johan Baeck; Gabriel Tremblay
Journal:  Breast Cancer (Dove Med Press)       Date:  2018-05-04
View more
  4 in total

1.  Unique structural features govern the activity of a human mitochondrial AAA+ disaggregase, Skd3.

Authors:  Ryan R Cupo; Alexandrea N Rizo; Gabriel A Braun; Eric Tse; Edward Chuang; Kushol Gupta; Daniel R Southworth; James Shorter
Journal:  Cell Rep       Date:  2022-09-27       Impact factor: 9.995

2.  m6A Methylation Regulators Are Predictive Biomarkers for Tumour Metastasis in Prostate Cancer.

Authors:  Yingchun Liang; Xiaohua Zhang; Chenkai Ma; Jimeng Hu
Journal:  Cancers (Basel)       Date:  2022-08-21       Impact factor: 6.575

Review 3.  Targeting the key cholesterol biosynthesis enzyme squalene monooxygenasefor cancer therapy.

Authors:  Yuheng Zou; Hongying Zhang; Feng Bi; Qiulin Tang; Huanji Xu
Journal:  Front Oncol       Date:  2022-08-24       Impact factor: 5.738

4.  USO1 expression is dysregulated in non-small cell lung cancer.

Authors:  Anna Keogh; Lisa Ryan; Mutaz M Nur; Anne-Marie Baird; Siobhan Nicholson; Sinéad Cuffe; Gerard J Fitzmaurice; Ronan Ryan; Vincent K Young; Stephen P Finn; Steven G Gray
Journal:  Transl Lung Cancer Res       Date:  2022-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.